Entyvio (vedolizumab) stays active in your system for roughly 3 to 4 months after your last infusion. The drug has a half-life of about 25 days, meaning it takes that long for your body to clear half of each dose. But measurable drug activity, specifically its effect on immune cells in your gut, can persist for 84 to 126 days (about 12 to 18 weeks) after the final dose, based on FDA clinical pharmacology data.
How Entyvio Leaves Your Body
Entyvio is a biologic antibody, not a small-molecule pill, so your body doesn’t process it through the liver or kidneys the way it handles most medications. Instead, it’s gradually broken down by your immune system, the same way your body recycles its own proteins. This slower breakdown is why biologics like Entyvio linger far longer than a typical oral medication.
With a half-life of roughly 25 days, the drug concentration drops by half every three and a half weeks or so. After one half-life, 50% remains. After two (about 7 weeks), 25% remains. After three (about 11 weeks), 12.5% remains. Most pharmacologists consider a drug functionally cleared after about five half-lives, which puts the total elimination window at approximately 4 to 5 months for Entyvio.
How Long the Drug’s Effects Last
Entyvio works by binding to a specific protein on the surface of certain immune cells, blocking them from migrating into the lining of your gut where they cause inflammation. In FDA review data, this binding stayed at near-complete saturation (close to 100% blockade) throughout the entire treatment period and continued for 84 to 126 days after the last dose. That means even once drug levels start falling, the immune-blocking effect persists for roughly 3 to 4 months.
This is an important distinction. The drug itself may reach very low concentrations in your blood within a couple of months, but its functional impact on your immune cells takes longer to fully wear off. If you’re stopping Entyvio and switching to another medication, your doctor will factor in this overlap.
Factors That Could Change Your Timeline
FDA population pharmacokinetic analyses found that most patient characteristics, including body weight, age (18 to 78), disease severity, prior use of other biologics, and use of common co-medications like azathioprine or methotrexate, did not have a clinically meaningful effect on how quickly the body processes Entyvio. This is somewhat unusual for a biologic, and it means the elimination timeline is relatively consistent from person to person.
One factor that can speed clearance is the development of antibodies against the drug itself. When your immune system recognizes Entyvio as foreign and builds antibodies to it, those antibodies essentially tag the drug for faster removal. This leads to lower drug levels in the blood and can shorten how long the medication remains active. Patients who develop these antibodies sometimes notice the drug wearing off sooner, which is one reason some people lose response to Entyvio over time.
What This Means for Switching or Stopping
If you’re stopping Entyvio to start a new biologic, your care team will typically allow a washout period to avoid overlapping two immune-suppressing therapies. Given Entyvio’s 3-to-4-month activity window, that waiting period can feel long, especially if your symptoms are flaring. In practice, the exact timing depends on why you’re switching and what you’re switching to, since Entyvio’s gut-specific mechanism carries less systemic immune suppression than many other biologics.
For pregnancy planning, current gastroenterology guidelines do not specify a required washout period for Entyvio the way they do for some other medications (methotrexate, for example, requires at least 3 months). Many specialists continue Entyvio during pregnancy when the benefits of controlling inflammatory bowel disease outweigh risks, but the decision is individualized.
Trough Levels and Monitoring
During active treatment, blood tests can measure your Entyvio trough level, which is the lowest concentration in your blood just before your next infusion. Trough levels above 14 μg/mL during maintenance therapy are associated with better outcomes in both ulcerative colitis and Crohn’s disease. After you stop the drug, trough levels gradually fall below detectable limits over the following weeks, generally tracking with the half-life timeline described above. If you’ve had blood work showing your levels were already low before stopping, the drug will leave your system on the shorter end of the 3-to-5-month window.